Liangjiang: An emerging pharmaceutical innovation hub

Liangjiang New Area is establishing itself as a central hub for pharmaceutical pilot platforms, with key players such as Boji Medical Technology Co, Porton Pharma Solutions, and ChemPion leading the charge.

These platforms offer comprehensive, one-stop services designed to accelerate the commercialization and transformation of scientific research achievements.

Chongqing Boji Pharmaceutical Co in Liangjiang's Shuitu New City is focused on developing a high-end shared biopharmaceutical R&D platform, an advanced medical device development platform, and a biopharmaceutical industry platform centered around an incubator.

The company has so far incubated eight pharmaceutical enterprises.

Also based in Shuitu New City, Porton Pharma Solutions offers services that include the development of small-molecule drugs, peptides, oligonucleotides, proteins, and conjugates, as well as cell and gene therapies.

Liangjiang currently hosts 25 platforms covering technical services, regulatory administration, industry incubation, scientific innovation, and clinical services.

The area is also optimizing its industrial ecosystem and enhancing its service systems, injecting momentum into the innovation and development of the biopharmaceutical industrial chain.